Peter Kuhn, PhD

University Professor, Dean's Professor of Biological Sciences and Professor of Biological Sciences, Medicine, Biomedical Engineering, Aerospace and Mechanical Engineering and Urology

Image of Peter Kuhn, PhD
Is this your profile? Click to edit

Overview

Peter Kuhn joined the USC Dana and David Dornsife College of Letters, Arts and Sciences as Dean’s Professor of Biological Sciences in July 2014. Dr. Kuhn also has appointments as Professor of Medicine, Professor of Biomedical Engineering and Professor of Aerospace & Mechanical Engineering, a founding member of the Michelson Center for Convergent Biosciences at USC and is leading CSI-Cancer at USC. He is a scientist, educator and entrepreneur with a career long commitment in personalized medicine and individualized cancer patient care. He is focused on the redesign of cancer care. The first product from technology developed by Dr. Kuhn became available for prostate cancer care in June 2016. Dr. Kuhn’s strategy is to advance our understanding of the human body to improve the human condition for those affected by cancer. His research is shedding new light at how cancer spreads through the body and evolves over time. This new science will lead to a personalized care strategy that is biologically informed and clinically actionable. He is a physicist who trained initially at the Julius Maximilians Universität Würzburg, Germany, before receiving his Masters in Physics at the University of Albany, Albany, NY in 1993 and his Ph.D. in 1995. He then moved to Stanford University where he joined the faculties of Medicine and Accelerator Physics as tenure track Assistant Professor. From 2002 to 2014 he established the Physics Oncology program at The Scripps Research in La Jolla, CA as tenured Associate Professor before joining USC in 2014. He has published over 200 peer scientific articles and patents resulting from his research.

Publications

  • Corrigendum to “Single-cell proteomic analysis reveals Multiple Myeloma heterogeneity and the dynamics of the tumor immune microenvironment in precursor and advanced states” [Neoplasia 66 (2025) 1101189]. Neoplasia. 2025 Nov; 69:101226.. View in PubMed
  • Representation learning enables robust single cell phenotyping in whole slide liquid biopsy imaging. Sci Rep. 2025 Oct 21; 15(1):36589.. View in PubMed
  • Automated Single-Cell Analysis in the Liquid Biopsy of Breast Cancer. Cancers (Basel). 2025 Aug 26; 17(17).. View in PubMed
  • Aqueous Humor Liquid Biopsy Identifies Murine Double Minute 4 Segmental Gain in Retinoblastoma: Implications for Chemotherapy Response and Precision Oncology. JCO Precis Oncol. 2025 Aug; 9:e2500250.. View in PubMed
  • Single-cell proteomic analysis reveals Multiple Myeloma heterogeneity and the dynamics of the tumor immune microenvironment in precursor and advanced states. Neoplasia. 2025 08; 66:101189.. View in PubMed
  • Simultaneous expression of epithelial and immune cell markers in circulating tumor cells identified in patients with stage 4 breast cancer. Commun Med (Lond). 2025 Jul 24; 5(1):309.. View in PubMed
  • Unsupervised detection of rare events in liquid biopsy assays. NPJ Precis Oncol. 2025 Jul 05; 9(1):225.. View in PubMed
  • Navigating Complexity: Perspectives on Risk Assessment in the Era of New Blood-Based Tests for Early Cancer Detection. Clin Cancer Res. 2025 Jun 13; 31(12):2267-2270.. View in PubMed
  • Minimum Technical Preanalytical, Patient, and Clinical Context Data Elements for Cerebrospinal Fluid Liquid Biopsy: Recommendations for Public Database Submissions. JCO Precis Oncol. 2025 Jun; 9:e2400921.. View in PubMed
  • Contrastive Representation Learning for Single Cell Phenotyping in Whole Slide Imaging of Enrichment-free Liquid Biopsy. bioRxiv. 2025 May 24.. View in PubMed